Cargando…
Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates
BACKGROUND: Olanzapine, regarded as one of the most efficacious antipsychotic medications for the treatment of schizophrenia, is associated with a high risk of weight gain and metabolic dysfunction. ALKS 3831, a clinical candidate for treatment of schizophrenia, is a combination of olanzapine and sa...
Autores principales: | Cunningham, Jacobi I, Eyerman, David J, Todtenkopf, Mark S, Dean, Reginald L, Deaver, Daniel R, Sanchez, Connie, Namchuk, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764014/ https://www.ncbi.nlm.nih.gov/pubmed/31294646 http://dx.doi.org/10.1177/0269881119856850 |
Ejemplares similares
-
Combining samidorphan with olanzapine to mitigate weight gain as a side effect in schizophrenia treatment
por: Grywińska, Weronika B., et al.
Publicado: (2023) -
Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers
por: Toledo, Frederico G. S., et al.
Publicado: (2021) -
In vivo Characterization of the Opioid Receptor–Binding Profiles of Samidorphan and Naltrexone in Rats: Comparisons at Clinically Relevant Concentrations
por: Tan, Laura A, et al.
Publicado: (2022) -
A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine
por: Srisurapanont, Manit, et al.
Publicado: (2021) -
The Facts and Fiction of Olanzapine-Samidorphan Fixed Dose Combination
por: Das, Nileswar, et al.
Publicado: (2022)